Participant flow

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia · Source last updated 2021-12-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Children and adolescents newly diagnosed with Philadelphia chromosome positive acute lymphocytic leukemia (Ph+ ALL) treated with standard multiagent chemotherapy and Dasatinib (either in tablets or Powder For Oral Suspension (PFOS)) at a dose of 60 mg/m2 daily.

   id

   FG000

   title

   Dasatinib Cohort

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Lack of Efficacy

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Study Drug Toxicity

   3. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Adverse Event

   4. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Withdrawal by Subject

   5. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Death

   6. reasons

      1. group Id

         FG000

         num Subjects

         9

      type

      Other reasons

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         106

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         78

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         28

      type

      NOT COMPLETED

   title

   Treatment Phase

2. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         14

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Lost to Follow-up

   4. reasons

      1. group Id

         FG000

         num Subjects

         70

      type

      Follow-up no longer required per protocol

   5. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Other and not reported reasons

   milestones

   1. achievements

      1. comment

         Some of the participants who did not completed the Treatment Phase were still moved to the Follow-up Phase

         group Id

         FG000

         num Subjects

         100

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      comment

      Completed = continuing in the follow-up phase

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         100

      type

      NOT COMPLETED

   title

   Follow-up Phase

pre Assignment Details

106 participants were treated with dasatinib.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice